Regulation of Differentiation by HBP1, a Target of the Retinoblastoma Protein

ABSTRACT

Differentiation is a coordinated process of irreversible cell cycle exit and tissue-specific gene expression. To probe the functions of the retinoblastoma protein (RB) family in cell differentiation, we isolated HBP1 as a specific target of RB and p130. Our previous work showed that HBP1 was a transcriptional repressor and a cell cycle inhibitor. The induction of HBP1, RB, and p130 upon differentiation in the muscle C2C12 cells suggested a coordinated role. Here we report that the expression of HBP1 unexpectedly blocked muscle cell differentiation without interfering with cell cycle exit. Moreover, the expression of MyoD and myogenin, but not Myf5, was inhibited in HBP1-expressing cells. HBP1 inhibited transcriptional activation by the MyoD family members. The inhibition of MyoD family function by HBP1 required binding to RB and/or p130. Since Myf5 might function upstream of MyoD, our data suggested that HBP1 probably blocked differentiation by disrupting Myf5 function, thus preventing expression of MyoD and myogenin. Consistent with this, the expression of each MyoD family member could reverse the inhibition of differentiation by HBP1. Further investigation implicated the relative ratio of RB to HBP1 as a determinant of whether cell cycle exit or full differentiation occurred. At a low RB/HBP1 ratio cell cycle exit occurred but there was no tissue-specific gene expression. At elevated RB/HBP1 ratios full differentiation occurred. Similar changes in the RB/HBP1 ratio have been observed in normal C2 differentiation. Thus, we postulate that the relative ratio of RB to HBP1 may be one signal for activation of the MyoD family. We propose a model in which a checkpoint of positive and negative regulation may coordinate cell cycle exit with MyoD family activation to give fidelity and progression in differentiation.

ACKNOWLEDGMENTS

We thank the following colleagues for their generosity: Eric Olson (myogenin, MyoD, Myf5, and MCK CAT), Woody Wright (antimyogenin F5D), Frank Stockdale (continuous supply of anti-MHC), and Yukang Wang (murine Myf5). We thank Eric Paulson, Andrew Leiter, Brian Schaffhausen, and Larry Feig for many helpful discussions. We especially thank Marie Classon, Ed Harlow, Bill Kaelin, and Wen-Hwa Lee for providing information prior to publication.

The work was supported by grants to A.S.Y. from the AHA, the NIH (GM44634), and the Digestive Disease Center at New England Medical Center (NIDDK, P30 DK-34928). A.S.Y. is an Established Investigator of the American Heart Association.